Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* understand and sign informed consent~* willing to undergo night blood sampling every 6 months for 2 years~* Age 18 to 55 years~* Haemoglobin of equal or above 9g/dl~* Microfilarial level of equal or above 80mg/dl~Exclusion Criteria:~* Non- consenting~* Pregnancy or lactation~* Treatment with albendazole or ivermectin within the previous 6 months~* Known allergy to the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- albendazole 400mg and ivermectin 200mcg/kg (Type: ACTIVE_COMPARATOR): Annual treatment
- Albendazole 800mg and ivermectin 400mcg/kg (Type: ACTIVE_COMPARATOR): Annual treatment
- Albendazole 400mg and ivermectin 200mcg/kg (Type: ACTIVE_COMPARATOR): albendazole 400mg and ivermectin 200mcg/kg given twice a year
- Albendazole 800mg and ivermectin 400mcg /kg bi-annually (Type: ACTIVE_COMPARATOR): Albendazole 800mg and ivermectin 400mcg/kg given twice a year

Based on this trial design, predict the completion outcome and termination type (if applicable).